Correlation between COX-2 Expression and Hormone Receptors in Invasive Ductal Breast Cancer
|
|
- Homer Flowers
- 5 years ago
- Views:
Transcription
1 J Korean Surg Soc 2010;78: DOI: /jkss 원 저 Correlation between COX-2 Expression and Hormone Receptors in Invasive Ductal Breast Cancer Departments of Breast and Endocrine Surgery and 1 Pathology, Korea University Hospital, Seoul, Korea Jung Ah Lee, M.D., Jeoung Won Bae, Ph.D., Sang Uk Woo, Ph.D., Hyunchul Kim, M.D. 1, Chul Hwan Kim, Ph.D. 1 Purpose: COX-2 is known to be elevated in breast cancer, but the clinical relevance is still a matter of debate. The purpose of this study was to determine the prognostic significance and relationship of COX-2 to hormone receptors. Methods: Between January 2005 and February 2007, 80 specimens from breast cancer patients at Korea University Anam Hospital were reviewed by one pathologist. COX-2 was analyzed as overexpressed if >10% of the cells were stained. Clinical characteristics, hormone receptor status, and other prognostic factors were investigated to determine their association with COX-2 expression. Results: COX-2 was overexpressed in 12 patients (15%). Two patients had locoregional recurrence, eight patients had systemic metastasis, and one patient died. There was no statistically significant correlation between COX-2 expression and age, size, nodal status, histological grade, hormone receptor status, and HER-2/neu positivity. Among tumors that had a positive expression of ER and PR, COX-2 expression was related to larger size ( and 0.009, respectively) and nodal status ( and 0.009, respectively). However, there was no statistically significant correlation with tumors that had negative ER or PR expression. Conclusion: This study suggests that in breast cancer, COX-2 expression has no relationship with clinicopathologic factors; however, a correlation was noted in size and nodal status for ER- and PR-positive tumors. Further prospective study with larger population to clarify the relationship between COX-2 expression and hormone receptor status is necessary. (J Korean Surg Soc 2010;78: ) Key Words: Cyclooxygenase 2, Breast cancer, Estrogen receptor, Progesterone receptor INTRODUCTION Correspondence to: Jeoung Won Bae, Department of Breast and Endocrine Surgery, Korea University Anam Hospital, Korea University College of Medicine, 126-1, Anam-dong 5-ga, Seongbuk-gu, Seoul , Korea. Tel: , Fax: , kujwbae@korea.ac.kr Received October 28, 2009, Accepted December 14, Estrogen is an important factor in the etiology of breast cancer. It is regulated by the cytochrome P-450 enzyme complex known as aromatase, which catalyzes androgen to produce estrogen. Cyclooxygenase-2 (COX-2) plays a role in the regulation of estrogen since it produces prostaglandin E2, which increases the expression of the cytochrome P-450 enzyme complex. Prostaglandin E2 is produced not only by COX-2, but by COX-1. However, COX-1 is constitutively produced by most tissues, while COX-2 is induced in the environment with mitogens, cytokines, hormones, and serum. Molecular studies suggest that COX-2 is related to mutagenesis, angiogenesis, inhibition of apoptosis, and aromatase-catalyzed estrogen biosynthesis; there is also a hypothesis that local estrogen levels induced by elevated aromatase activity stimulate tumor growth, thus the development and role of COX-2 seems to be essential in breast cancer.(1-5) COX-2 is known to be expressed in several cancers, including colorectal, prostate, lung, pancreas, and breast. (6-11) Moreover, many studies suggest that COX-2 is a prognostic factor for various cancers, especially colorectal
2 Jung Ah Lee, et al:cox-2 in Invasive Ductal Breast Cancer 141 adenocarcinomas.(8) Based on these theories, targeting COX-2 is thought to be an effective strategy for treatment, which has given rise to clinical trials with COX-2 inhibitors, such as celecoxib and rofecoxib for colorectal cancer.(12) COX-2 selective inhibitors suppress tumorigenesis in rat models of breast cancer,(13) but unlike colorectal cancer, studies relating COX-2 to breast cancer have not shown consistency with respect to clinicopathologic and prognostic significance. Although estrogen is clearly related to COX-2, the relationship between COX-2 and the estrogen receptor (ER) for breast cancer is unclear. The aim of this study was to investigate the prognostic significance of COX-2 and its relationship to the hormone receptors. METHODS 1) Patients We identified 80 patients who were diagnosed with breast cancer at Korea University Anam Hospital between January 2005 and February 2007; their specimens were collected retrospectively. The patients were all females who were diagnosed with invasive ductal carcinoma by light microscopy using conventional hematoxylin and eosin stain, and underwent modified radical mastectomy or breast-conserving surgery. The baseline patient characteristics are summarized in Table 1. Among 80 patients, 57 patients underwent axillary node dissection, while 23 patients had negative results on sentinel lymph node biopsy. Patients who did not have surgical treatment were excluded. Adjuvant chemotherapy was administered according to the pathologic report and all patients who underwent breast-conserving surgery received radiation therapy and those who were hormone receptor-positive had adjuvant hormonal therapy. Size and nodal status were divided using the criteria of the TNM system. Histological grade was evaluated using the Bloom and Richardson criteria as guidelines suggested by the Nottingham City Hospital Pathologists.(14) 2) Immunohistochemistry Archived paraffin-embedded tissue samples were studied. Table 1. Patient characteristics Characteristics No. of patients (%) All patients COX-2 expression Overexpressed (+) Unexpressed ( ) Age (yrs) > Tumor size (cm) < < Lymph node status < Histological grade Estrogen receptor status Positive Negative Progesterone receptor status Positive Negative HER2/neu expression Positive Negative Ki-67 expression <20% % p-53 Positive Negative Distant metastasis Yes 8 10 No Death Yes No Two consecutive 4μm-thick sections were cut from the paraffin-embedded block. One section from the specimen was routinely stained with hematoxylin-and-eosin. Another section was immunohistochemically stained for COX-2. Tissue sections were deparaffinized in xylene, and rehydrated with a graded series of ethanol to water. The activity of peroxidase was inhibited by precipitation in
3 142 J Korean Surg Soc. Vol. 78, No. 3 Fig. 1. Cox-2 immunohistochemical staining in invasive ductal breast carcinoma. (A) Negative immunoreactivity (H&E stain, 400). (B) Positive immunoreactivity in cytoplasm of >10% of tumor cells (H&E stain, 400). methanol with 3% H 2 O 2 for 5 minutes. The slides were cooked with Tris-EDTA buffer (ph 9.0) in an autoclave at 121 o C for 5 minutes for COX-2. Samples were incubated with COX-2 antibody (1:100; Dako, Copenhagen, Denmark) at room temperature for 30 minutes. After washing, the sections were incubated with a secondary antibody (ChemMate DAKO Envision) at room temperature for 30 minutes. Subsequently, the sections were subjected to DAB (substrate buffer+dab chromogen [X50]) for 5 minutes. The slides were counterstained with hematoxylin and then mounted. COX-2 cytoplasmic evaluation was made by intensity scored as 0 (negative), 1 (weak), 2 (moderate), or 3 (strong) and percentage of positive tumor cells. COX-2 was considered overexpressed when the intensity was scored with 2 and 3 with more than 10% of positive tumor cells (Fig. 1). Assessment of ER and progesterone receptor (PR) status was done by standard immunohistochemical methods and considered positive if the value was >10% of nuclear staining. Evaluation was done by single pathologist using a light microscope. 3) Statistical analysis Comparison of clinicopathologic factors between COX-2 overexpressed and unexpressed patients were assessed using SPSS, version 12. Chi-square tests were used for univariate analysis, and logistic regression with forward procedure was used for statistically significant factors in multivariate analysis. For comparison of disease-free survival, Kaplan- Meier survival curves were used. Statistical significance was regarded when the was <0.05. RESULTS The correlation between clinicopathologic factors and COX-2 expression of 80 patients are summarized in Table 2. There were 12 patients with overexpressed COX-2 and 68 patients with unexpressed COX-2, with a positivity rate of 15%. No statistical significance was found between COX-2 overexpressed patients and COX-2 unexpressed patients with respect to age, tumor size, nodal status, and hormone receptors status. The mean follow-up period was ±8.266 months. Eight patients developed distant metastasis (two patients in the liver and bone, three patients in bone only, two patients in the lungs, and one patient in the brain). One patient had breast recurrence and one patient died. We divided the group into ER-positive and -negative groups to compare the differences in clinicopathologic factors between COX-2-overexpressed and -unexpressed patients in each group. Comparison of the ER and PR
4 Jung Ah Lee, et al:cox-2 in Invasive Ductal Breast Cancer 143 Table 2. Correlation between COX-2 expression and clinicopathologic factors Characteristics COX-2 (+) (%) COX-2 ( ) (%) Age (yrs) (13.2) 33 (86.8) >50 7 (16.7) 35 (83.3) Tumor size (cm) <2 4 (10.3) 35 (89.7) 2 <5 6 (17.1) 29 (82.9) 5 2 (33.3) 4 (66.7) Lymph node status (9.8) 37 (90.2) (16.7) 15 (83.3) (33.3) 6 (66.7) 10< 2 (16.7) 10 (83.3) Histological grade (0) 15 (100) 2 4 (14.3) 24 (85.7) 3 7 (20) 28 (80) Estrogen receptor status Positive 6 (11.8) 45 (88.2) Negative 6 (20.7) 23 (79.3) Progesterone receptor status Positive 5 (11.1) 40 (88.9) Negative 7 (20) 28 (80) HER2/neu expression Positive 2 (8.3) 22 (91.7) Negative 10 (17.9) 46 (82.1) Ki-67 expression 0.23 <20% 1 (5.9) 16 (94.1) 20% 11 (17.7) 51 (82.3) p Positive 8 (21.6) 29 (78.4) Negative 4 (9.3) 39 (90.7) Distant metastasis Yes 2 (25) 6 (75) No 10 (13.9) 62 (86.1) Death Yes 0 (0) 1 (100) No 12 (15) 67 (85) group is outlined in Table 3 and 4. COX-2 overexpression was more common in larger tumors and higher nodal status with s of <0.001 and 0.048, respectively. Larger size and higher nodal status was more commonly positive for COX-2 overexpression patients in the PRpositive group (Table 4) with a of However in multivariate analysis, no correlation was found between clinicopathologic parameters and COX-2 expression. There were no statistically significant factors in the ER-negative group and PR-negative group. There were no differences in disease-free survival according to COX-2 positivity with a of (Fig. 2). Disease-free survival was compared according to ER and PR status, but statistical significance was not found (Fig. 3). DISCUSSION Many factors are known to be prognostic factors for breast cancers, including size, nodal status, hormone receptors, and HER2/neu expression. For targeting treatment, hormone therapy and targeting HER2/neu have been successful and they have become the mainstay of treatment of breast cancer patients along with chemotherapy and radiation therapy. Adding to these treatment strategies, different factors are being studied, one of which is COX-2. Brueggemeier et al.(1,2) showed the regulation of estrogen in relation to COX-2, and concluded that elevation of COX-2 expression results in increased aromatase activity via autocrine and paracrine mechanisms which underlie the pathogenesis of breast cancer. Although there are theories involving the relationship between COX-2 and breast cancer, clinical relevance or prognostic values are still controversial, thus we attempted to determine the relationship between clinicopathologic factors and COX-2 expression. The positivity of COX-2 in breast cancer varies from 4.5% to 85%,(6,15) and in our study 15% of all invasive ductal cancers had an elevated expression of COX-2. The reason for variation in the positivity of COX-2 appears to be because of an unclear definition and inconsistency of increased COX-2 in most of the studies. Cho et al.(16) determined COX-2 by multiplying the staining intensity score and staining quantity score, while Ristimaki et al.(6) and Haffty et al.(17) considered COX-2 moderately-tostrongly positive when >10% was stained in cancer cells, which was how we evaluated COX-2 positivity herein. This study was conducted to determine the significance of COX-2 in breast cancer, but we found no association between clinicopathologic factors, including age, tumor size, nodal status, histological grade, hormone receptor
5 144 J Korean Surg Soc. Vol. 78, No. 3 Table 3. Correlation between COX-2 expression and clinicopathologic factors according to estrogen receptor status Characteristics Estrogen receptor status Positive (%) Negative (%) COX-2 (+) COX-2 ( ) COX-2 (+) COX-2 ( ) Age (yrs) (12.5) 21 (87.5) 2 (14.3) 12 (85.7) >50 3 (11.1) 24 (88.9) 4 (26.7) 11 (73.3) Tumor size (cm) < <2 1 (3.7) 26 (96.3) 3 (25) 9 (75) 2 <5 3 (13.6) 19 (86.4) 3 (23.1) 10 (76.9) 5 2 (100) 0 (0) 0 (0) 4 (100) Lymph node status (4) 24 (96) 3 (18.8) 13 (81.3) 1 2 (13.3) 13 (86.7) 1 (33.3) 2 (66.7) 2 1 (25) 3 (75) 2 (40) 3 (60) 3 2 (28.6) 5 (71.4) 0 (0) 5 (100) Histological grade (0) 13 (100) 0 (0) 2 (100) 2 3 (13.6) 19 (86.4) 1 (16.7) 5 (83.3) 3 2 (13.3) 13 (86.7) 5 (25) 15 (75) HER2/neu Positive 1 (7.7) 12 (92.3) 1 (9) 10 (91) Negative 5 (13.2) 33 (86.8) 5 (27.7) 13 (72.3) Ki-67 expression <20% 1 (6.3) 15 (93.8) 0 (0) 1 (100) 20% 5 (14.3) 30 (85.7) 6 (22.2) 21 (77.8) p Positive 3 (15) 17 (85) 5 (29.4) 12 (70.6) Negative 3 (9.7) 28 (90.3) 1 (8.3) 11 (91.7) Distant metastasis Yes 0 (0) 2 (100) 2 (33.3) 4 (66.7) No 6 (12.2) 43 (87.8) 4 (17.3) 19 (82.7) Death NS Yes 0 (0) 1 (100) 0 (0) 0 (0) No 6 (12) 44 (88) 6 (20.7) 23 (79.3) status, and COX-2 expression. We also attempted to determine a relationship with other prognostic factors, such as ki-67 and p-53, but there was no statistical significance; this result was consistent with other studies. Kelly et al.(15) studied 106 breast cancer patients and found no statistical correlation between COX-2 expression level and other prognostic indicators, such as node status, tumor size, histological grade, histology, and ER or PR status. Thorat et al.(18) tried to find a relationship between COX-2 expression and microvessel density in breast cancer. The histological grade and ER status were the only factors to correlate with COX-2 status.(18) However, in Finland, Ristimaki et al.(6) conducted a multicenter study with a large population of 1,576 patients with invasive ductal breast carcinoma, concluding that COX-2 overexpression was related to poor prognosis with reduced survival. Unlike other studies, Denkert et al.(19) examined both isoforms of cyclooxygenase with 221 primary breast cancer patients. COX-1 and COX-2 were overexpressed in 45.5% and 36.2% of all patients, respectively. COX-1 is known to be expressed in most normal tissues, and likewise only COX-2 expression was associated with prognosis and tumor size, histological grade, nodal status, and angioinvasion. In previous animal studies, celecoxib, a COX-2 inhibitor, was
6 Jung Ah Lee, et al:cox-2 in Invasive Ductal Breast Cancer 145 Table 4. Correlation between COX-2 expression and clinicopathologic factors according to progesterone receptor status Characteristics Progesterone receptor status Positive (%) Negative (%) COX-2 (+) COX-2 ( ) COX-2 (+) COX-2 ( ) Age (yrs) (9.1) 20 (90.9) 3 (18.8) 13 (81.3) >50 3 (13) 20 (87) 4 (21.1) 15 (78.9) Tumor size (cm) <2 1 (4) 24 (96) 3 (21.4) 11 (78.6) 2 <5 2 (11.8) 15 (88.2) 4 (22.2) 14 (77.8) 5 2 (66.7) 1 (33.3) 0 (0) 3 (100) Lymph node status (0) 21 (100) 4 (20) 16 (80) 1 2 (86.7) 13 (13.3) 1 (33.3) 2 (66.7) 2 1 (33.3) 2 (66.7) 2 (33.3) 4 (66.7) 3 2 (33.3) 4 (66.7) 0 (0) 6 (100) Histological grade (0) 11 (100) 0 (0) 4 (100) 2 2 (10) 18 (90) 2 (25) 6 (75) 3 2 (15.4) 11 (84.6) 5 (22.7) 17 (77.3) HER2/neu Positive 1 (9) 10 (91) 1 (7.7) 12 (92.3) Negative 4 (11.8) 30 (88.2) 6 (27.3) 16 (72.7) Ki-67 expression <20% 0 (0) 15 (1,005) 1 (50) 1 (50) 20% 5 (16.7) 25 (83.3) 6 (18.8) 26 (81.3) p Positive 3 (17.6) 14 (82.4) 5 (25) 15 (75) Negative 2 (7.1) 26 (92.9) 2 (13.3) 13 (86.7) Distant metastasis Yes 0 (0) 1 (100) 2 (28.6) 5 (71.4) No 5 (11.4) 39 (88.6) 5 (17.8) 23 (82.2) Death NS Yes 0 (0) 1 (100) 0 (0) 0 (0) No 5 (11.4) 39 (88.6) 7 (20) 28 (80) reported to be more effective in reducing tumor development and volume than ibuprofen, a non-specific cyclooxygenase inhibitor,(20-22) which was consistent with the report of Denkert et al.(19) regarding the prognosis. Inconsistent results of relationship between COX-2 expression and other clinicopathological factors or prognosis remains undetermined. However, it could be explained by lack of clarified mechanism of increased COX-2 expression in breast cancer and subjective evaluation of COX-2 staining. Although COX-2 expression was not associated with clinicopathological factors in our study, it would be interesting to conduct a well-designed study with a larger population and well-developed objective definition of COX-2 expression to further determine the effectiveness of COX-2 inhibitors for breast cancer therapy and prevention. Ristimaki et al.(6) not only compared the prognostic factors with COX-2 expression, but they compared clinical factors in different subgroups of patients. Patients with a positive ER tend to derive more prognostic value with COX-2 than the ER-negative group, but they did not have results for correlation with clinical factors. We compared clinicopathologic factors in ER, PR positive and negative groups. Larger size and higher nodal status was related to COX-2 positivity in the ER-positive group and the same
7 146 J Korean Surg Soc. Vol. 78, No. 3 was found with the PR-positive group, while there were no significant factors in the ER/PR negative groups. Survival curves, except for disease-free survival, could not Fig. 2. Disease-free survival (DFS) according to COX-2 expression. be evaluated in this study because of the short follow-up period. There were no significant differences in disease-free survival. Since COX-2 regulates estrogen in an autocrine or paracrine pathway, there appears to be a relationship with receptor status. Ristimaki et al.(6) suggested that elevated COX-2 expression in ER-positive cancers could enhance a microenvironment for cancer cells to grow by inducing estrogen production. Haffty et al.(17) reported a correlation between COX-2 expression and younger age, tumor size, higher breast relapse rates, more distant metastases, and mortality. They also reported that in the ERpositive group there was a stronger association with prognosis than in the ER-negative group. Although there are controversies of prognostic relevance of COX-2 expression, preclinical studies suggest the interconnection between aromatase and COX-2 pathways.(1,2,5,23) Based on these Fig. 3. Disease-free survival (DFS) comparison by hormone receptor status. (A) ER positive group. (B) ER negative group. (C) PR negative group. Survival curve couldn t be drawn in PR positive group because of small number of events.
8 Jung Ah Lee, et al:cox-2 in Invasive Ductal Breast Cancer 147 reports, several clinical trials investigated combination therapy with aromatase inhibitor (AI) and COX-2 inhibitor. The Celecoxib Anti-Aromatase Neoadjuvant (CAAN) trial treated 82 postmenopausal advanced breast cancer patients in three groups, exemestane and celecoxib, exemestane alone and letrozole alone for 3 months before surgery. The preliminary report shows overall response rate was 58.6% for combination therapy, 54.5% for exemestane alone group and 62% for letrozole alone group. They suggested that COX-2 inhibitor contribution is yet to be determined since they are still in initial phase of study.(24) Falandry et al.(23) designed a study comparing treatment between exemestane with celecoxib and exemestane with placebo for postmenopausal metastatic breast cancer patients resistant to tamoxifen therapy. The study started as a multicenter double-blinded randomized phase III trial involving 62 sites in France but terminated early after other trials with celecoxib reported cardiovascular toxicity. However, with 157 patients, they reported longer progression-free survival with tamoxifen-resistant patients who were treated with exemestane and celecoxib than with placebo (8.4 vs 4.7 months).(1-4) As mentioned earlier, the mechanism has not been distinct but there are studies suggesting the interconnection(5) and there are ongoing clinical trials for verification.(23) The relationship between HER-2/neu and COX-2 has also been established. Several reports have concluded that HER-2/neu overexpression increase COX-2 via the Raspathway.(25-27) Howe et al.(27) reported that when there is COX-2 deficiency in HER2/neu highly expressed breast cancer, tumor formation and growth decreases and this was shown with COX-2 knock-out mice. These results may lead us to use COX-2 inhibitor as a prevention of breast cancer with HER2/neu-overexpressed cancer. However, this study suggests that there is an inverse relationship between HER2/neu expression and COX-2 positivity, although there was no significance. The absence of a relationship with COX-2 and clinicopathologic factors was inconclusive since the population was small, with 80 invasive ductal carcinoma tissues, and may have selection bias as it was a retrospective study. Also, there is yet no agreement concerning the definition of COX-2 positivity and we think this might be a priority matter internationally. In conclusion, we identified no correlation between clinicopathologic factors and COX-2 expression, but size and nodal status appear to be related to COX-2 positivity in the ER-positive group and controversies still remain for the clinical significance of COX-2 expression. REFERENCES 1) Brueggemeier RW, Diaz-Cruz ES, Li PK, Sugimoto Y, Lin YC, Shapiro CL. Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer. J Steroid Biochem Mol Biol 2005;95: ) Brueggemeier RW, Richards JA, Petrel TA. Aromatase and cyclooxygenases: enzymes in breast cancer. J Steroid Biochem Mol Biol 2003;86: ) Diaz-Cruz ES, Shapiro CL, Brueggemeier RW. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 2005;90: ) Richards JA, Petrel TA, Brueggemeier RW. Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells. J Steroid Biochem Mol Biol 2002;80: ) Brodie AM, Lu Q, Long BJ, Fulton A, Chen T, Macpherson N, et al. Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem Mol Biol 2001;79: ) Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62: ) Kokawa A, Kondo H, Gotoda T, Ono H, Saito D, Nakadaira S, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001;91: ) Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995;55: ) Tjandrawinata RR, Dahiya R, Hughes-Fulford M. Induction of cyclo-oxygenase-2 mrna by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer 1997;75: ) Castelao JE, Bart RD 3rd, DiPerna CA, Sievers EM, Bremner RM. Lung cancer and cyclooxygenase-2. Ann Thorac Surg 2003;76: ) Jang HR, Yang KH, Bae BN, Kim KH, Han SH, Kim HJ, et al. The clinical significance of cyclooxygenase 2 expression in colorectal cancer. J Korean Surg Soc 2003;64: ) Buecher B, Bouancheau D, Broquet A, Bezieau S, Denis MG, Bonnet C, et al. Growth inhibitory effect of celecoxib and
9 148 J Korean Surg Soc. Vol. 78, No. 3 rofecoxib on human colorectal carcinoma cell lines. Anticancer Res 2005;25: ) Connolly EM, Harmey JH, O'Grady T, Foley D, Roche-Nagle G, Kay E, et al. Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer. Br J Cancer 2002;87: ) Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey J, Sterrett G, et al. Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 1995;26: ) Kelly LM, Hill AD, Kennedy S, Connolly EM, Ramanath R, Teh S, et al. Lack of prognostic effect of Cox-2 expression in primary breast cancer on short-term follow-up. Eur J Surg Oncol 2003;29: ) Cho MH, Yoon JH, Jaegal YJ, Choi YD, Lee JS, Lee JH, et al. Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma. Breast 2006;15: ) Haffty BG, Yang Q, Moran MS, Tan AR, Reiss M. Estrogendependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breastconserving surgery and radiation. Int J Radiat Oncol Biol Phys 2008;71: ) Thorat MA, Mehrotra S, Morimiya A, Badve S. COX-2 expression does not correlate with microvessel density in breast cancer. Pathobiology 2009;76: ) Denkert C, Winzer KJ, Muller BM, Weichert W, Pest S, Kobel M, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 2003;97: ) McCormick DL, Moon RC. Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal antiinflammatory agent. Br J Cancer 1983;48: ) Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000;60: ) Alshafie GA, Abou-Issa HM, Seibert K, Harris RE. Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 2000;7: ) Falandry C, Canney PA, Freyer G, Dirix LY. Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Ann Oncol 2009;20: ) Chow LW, Yip AY, Loo WT, Lam CK, Toi M. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol 2008;111: ) Benoit V, Relic B, Leval Xd X, Chariot A, Merville MP, Bours V. Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2. Oncogene 2004;23: ) Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 2002;277: ) Howe LR, Chang SH, Tolle KC, Dillon R, Young LJ, Cardiff RD, et al. HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res 2005;65:
Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationThe importance of COX-2 expression as prognostic factor in early breast cancer
JBUON 2013; 18(3): 579-584 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE The importance of COX-2 expression as prognostic factor in early breast
More informationAre there the specific prognostic factors for triplenegative subtype of early breast cancers (pt1-2n0m0)?
Are there the specific prognostic factors for triplenegative subtype of early breast cancers (pt1-2n0m0)? Department of General Surgery, Anam Hospital, Korea University, College of Medicine, 126-, Anam-dong
More informationEstrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women
Journal of Bangladesh College of Physicians and Surgeons Vol. 28, No. 3, September 2010 Estrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women
More informationSCIENCE CHINA Life Sciences
SCIENCE CHINA Life Sciences RESEARCH PAPER April 2013 Vol.56 No.4: 335 340 doi: 10.1007/s11427-013-4435-y Risk factors of recurrence in small-sized, node negative breast cancer in young women: a retrospective
More informationClaudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression
Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Mona A. Abd-Elazeem, Marwa A. Abd- Elazeem Pathology department, Faculty of Medicine, Tanta
More informationResults of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
More informationA comparison of Ki 67 proliferative index in primary tumor and axillary metastatic lymph nodes with length of survival in patients with breast cancer
DOI: 10.4149/BLL_2013_138 Bratisl Lek Listy 2013; 114 (11) CLINICAL STUDY A comparison of Ki 67 proliferative index in primary tumor and axillary metastatic lymph nodes with length of survival in patients
More informationP atients with primary breast cancer have an increased risk of developing contralateral breast cancer1. When
OPEN SUBJECT AREAS: BONE METASTASES BREAST CANCER Received 23 July 2013 Accepted 19 August 2013 Published 5 September 2013 Correspondence and requests for materials should be addressed to C.W.D. (ducaiwen@
More informationEvaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients
BIOSCIENCES BIOTECHNOLOGY RESEARCH ASIA, December 2015. Vol. 12(3), 2221-2225 Evaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients S.M. Hosseini¹, H. Shahbaziyan
More informationCorrelation between estrogen receptor β expression and the curative effect of endocrine therapy in breast cancer patients
1568 Correlation between estrogen receptor β expression and the curative effect of endocrine therapy in breast cancer patients LIYING GUO 1, YU ZHANG 2, WEI ZHANG 3 and DILIMINA YILAMU 1 1 Department of
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationHigh expression of fibroblast activation protein is an adverse prognosticator in gastric cancer.
Biomedical Research 2017; 28 (18): 7779-7783 ISSN 0970-938X www.biomedres.info High expression of fibroblast activation protein is an adverse prognosticator in gastric cancer. Hu Song 1, Qi-yu Liu 2, Zhi-wei
More informationModified primary tumour/vessel tumour/nodal tumour classification for patients with invasive ductal carcinoma of the breast
British Journal of Cancer (2011) 105, 698 708 All rights reserved 0007 0920/11 www.bjcancer.com Modified primary tumour/vessel tumour/nodal tumour classification for patients with invasive ductal carcinoma
More informationRadiation Therapy for the Oncologist in Breast Cancer
REVIEW ARTICLE Chonnam National University Medical School Sung-Ja Ahn, M.D. Adjuvant Tamoxifen with or without in Patients 70 Years of Age with Stage I ER-Positive Breast Cancer: Efficacy Outcomes (10
More informationHer-2/neu expression and its correlation with ER status and various clinicopathological parameters
Original Research Article DOI: 10.5958/2394-6792.2016.00106.X Her-2/neu expression and its correlation with ER status and various clinicopathological parameters Kriti Chauhan 1,*, Monika Garg 2, Abhimanyu
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationPosition Statement on Management of the Axilla in Patients with Invasive Breast Cancer
- Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationIMMUNOHISTOCHEMICAL EXPRESSION OF TISSUE INHIBITOR OF METALLOPROTEINASE-1 (TIMP-1) IN INVASIVE BREAST CARCINOMA
& IMMUNOHISTOCHEMICAL EXPRESSION OF TISSUE INHIBITOR OF METALLOPROTEINASE-1 (TIMP-1) IN INVASIVE BREAST CARCINOMA Suada Kuskunović*, Svjetlana Radović, Mirsad Dorić, Ajna Hukić, Mirsad Babić, Ivana Tomić,
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides
More informationBasement membrane in lobule.
Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.
More informationHypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor survival in breast cancer patients
Journal of BUON 17: 663-668, 2012 2012 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Hypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/55957 holds various files of this Leiden University dissertation Author: Dekker T.J.A. Title: Optimizing breast cancer survival models based on conventional
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationOriginal Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical outcome
Int J Clin Exp Pathol 2017;10(2):2030-2035 www.ijcep.com /ISSN:1936-2625/IJCEP0009456 Original Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical
More informationCase Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
More informationClinical Features and Survival Analysis of T1mic, a, bn0m0 Breast Cancer
Original Articles Jpn J Clin Oncol 2012;42(6)471 476 doi:10.1093/jjco/hys046 Advance Access Publication 3 April 2012 Clinical Features and Survival Analysis of T1mic, a, bn0m0 Breast Cancer Junnan Li,
More informationAnalysis of the outcome of young age tongue squamous cell carcinoma
Jeon et al. Maxillofacial Plastic and Reconstructive Surgery (2017) 39:41 DOI 10.1186/s40902-017-0139-8 Maxillofacial Plastic and Reconstructive Surgery RESEARCH Open Access Analysis of the outcome of
More informationAnnals of Diagnostic Pathology 10 (2006)
Annals of Diagnostic Pathology 10 (2006) 327 332 The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal
More informationClinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy
Case Series Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy Ling Xu 1*, Fang Li 1,2*, Yinhua Liu 1, Xuening Duan 1, Jingming Ye 1,
More informationCorrelation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer
Correlation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer X.L. Liu 1, L.D. Liu 2, S.G. Zhang 1, S.D. Dai 3, W.Y. Li 1 and L. Zhang 1 1 Thoracic Surgery,
More informationJournal of Breast Cancer
Journal of Breast Cancer ORIGINAL ARTICLE J Breast Cancer 2011 June; 14(2): 104-111 D2-40, Podoplanin, and CD31 as a Prognostic Predictor in Invasive Ductal Carcinomas of the Breast Jung Ah Lee, Jeoung
More informationBreast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C, Heidel RE, Desai P, McLoughlin J, Panella T, Bell
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationClinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
ORIGINAL ARTICLE 2018 Mar 16. [Epub ahead of print] Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy Mi Hwa Heo, Hee Kyung Kim,
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationThe Clinical Significance of. Triple-negative Phenotype on. Cancer Patients
The Clinical Significance of Triple-negative Phenotype on Prognosis of Young Age( 35) Breast Cancer Patients IM-KYUNG KIM Department of Medicine The Graduate School, Yonsei University The Clinical Significance
More informationW omen under 35 years of age form only a small
323 ORIGINAL ARTICLE Immunohistochemical prognostic index for breast cancer in young women I Guerra, J Algorta, R Díaz de Otazu, A Pelayo, J Fariña... See end of article for authors affiliations... Correspondence
More informationTable S2. Expression of PRMT7 in clinical breast carcinoma samples
Table S2. Expression of PRMT7 in clinical breast carcinoma samples (All data were obtained from cancer microarray database Oncomine.) Analysis type* Analysis Class(number sampels) 1 2 3 4 Correlation (up/down)#
More informationComparison of survival outcomes between modified radical mastectomy and breast conserving surgery in early breast cancer patients
http://dx.doi.org/10.7180/kmj.2016.31.1.19 KMJ Original Article Comparison of survival outcomes between modified radical mastectomy and breast conserving surgery in early breast cancer patients Yoon Seok
More informationBreast Carcinoma in Pakistani Females: A. Morphological Study of 572 Breast Specimens
Breast Carcinoma in Pakistani Females: A. Morphological Study of 572 Breast Specimens M. Shahid Siddiqui,Naila Kayani,Sara Sulaiman,Akbar S. Hussainy,Sajid H. Shah,Suhail Muzaffar ( Faculty of Health Sciences,
More informationExpression and significance of Bmi-1 and Ki67 in colorectal carcinoma tissues
[Chinese Journal of Cancer 27:12, 568-573; December Expression 2008]; 2008 and significance Sun Yat-sen of University Bmi-1 and Cancer Ki67 in Center colorectal carcinoma tissues Clinical Research Paper
More informationOverview of breast cancerpatients and their prognostic factors treated in Baghdad teaching hospital/ oncology department in the year 2010
Original Article Overview of breast cancerpatients and their prognostic factors treated in Baghdad teaching hospital/ oncology department in the year 21 * DMRT clinical oncology, MSc. pathology. Summary:
More informationThe Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer
The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer Cancer The Biology Century Understanding and treating the underlying tumor biology Cancer genetic studies demonstrate
More informationDeepa Taggarshe MD MRCS M Phil, Catherine Lobocki MS, Alasdair McKendrick MD FACS, Vijay K Mittal MD FACS
Clinicopathological significance of expression of Estrogen Receptor-Beta (ERβ), Progesterone Receptor(PR) and Vascular Endothelial Growth Factor- A (VEGF) in colorectal cancer. Deepa Taggarshe MD MRCS
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationAndrogen Receptor Expression in Estrogen Receptor Negative Breast Cancer Immunohistochemical, Clinical, and Prognostic Associations
Anatomic Pathology / ANDROGEN RECEPTOR IN BREAST CANCER Androgen Receptor Expression in Estrogen Receptor Negative Breast Cancer Immunohistochemical, Clinical, and Prognostic Associations S. Nicholas Agoff,
More informationLocoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
More informationOpen Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right
More informationHormone receptor and Her2 neu (Her2) analysis
ORIGINAL ARTICLE Impact of Triple Negative Phenotype on Breast Cancer Prognosis Henry G. Kaplan, MD* and Judith A. Malmgren, PhD à *Swedish Cancer Institute at Swedish Medical Center; HealthStat Consulting
More informationResearch Article Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67
SAGE-Hindawi Access to Research International Breast Cancer Volume 20, Article ID 47957, 4 pages doi:0.406/20/47957 Research Article Stromal Expression of CD0 in Invasive Breast Carcinoma and Its Correlation
More informationBreast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationDebate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest
Debate Axillary dissection - con Prof. Dr. Rodica Anghel Institute of Oncology Bucharest Summer School of Oncology, third edition Updated Oncology 2015: State of the Art News & Challenging Topics Bucharest,
More informationA Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast
Original Research Article A Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast E. Rajesh Goud 1, M. Muralidhar 2*, M. Srinivasulu 3 1Senior
More informationEditorial Process: Submission:11/30/2017 Acceptance:01/04/2019
RESEARCH ARTICLE Editorial Process: Submission:11/30/2017 Acceptance:01/04/2019 in Non-Metastatic Triple-Negative Breast Cancer O Al jarroudi*, A Zaimi, S A Brahmi, S Afqir Abstract Introduction: Triple-negative
More informationPrognostic significance of nemo like kinase in nasopharyngeal carcinoma
MOLECULAR MEDICINE REPORTS 10: 131-136, 2014 Prognostic significance of nemo like kinase in nasopharyngeal carcinoma SIZE CHEN 1,2*, ZHIJIAN MA 3*, XUEMEI CHEN 4 and JIREN ZHANG 1 1 Department of Oncology,
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationClinical Study on Prognostic Factors and Nursing of Breast Cancer with Brain Metastases
Clinical Study on Prognostic Factors and Nursing of Breast Cancer with Brain Metastases Ying Zhou 1#, Kefang Zhong 1#, Fang Zhou* 2 ABSTRACT This paper aims to explore the clinical features and prognostic
More informationAssessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint
Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center of Northwestern University Classical
More informationObjectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration
Objectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration of endocrine therapy 4. Advances in HER2 directed
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationOutcomes of patients with inflammatory breast cancer treated by breast-conserving surgery
Breast Cancer Res Treat (2016) 160:387 391 DOI 10.1007/s10549-016-4017-3 EDITORIAL Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery Monika Brzezinska 1 Linda J.
More informationClinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy
Yang et al. World Journal of Surgical Oncology (2018) 16:51 https://doi.org/10.1186/s12957-018-1332-7 RESEARCH Open Access Clinical significance and prognostic value of receptor conversion in hormone receptor
More informationCharacterization and significance of MUC1 and c-myc expression in elderly patients with papillary thyroid carcinoma
Characterization and significance of MUC1 and c-myc expression in elderly patients with papillary thyroid carcinoma Y.-J. Hu 1, X.-Y. Luo 2, Y. Yang 3, C.-Y. Chen 1, Z.-Y. Zhang 4 and X. Guo 1 1 Department
More informationA study on clinicopathological features and prognostic factors of patients with upper gastric cancer and middle and lower gastric cancer.
Biomedical Research 2018; 29 (2): 365-370 ISSN 0970-938X www.biomedres.info A study on clinicopathological features and prognostic factors of patients with upper gastric cancer and middle and lower gastric
More informationPrognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer
Prognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer Hee Jung Kwon, Nuri Jang, Min Hui Park, Young Kyung Bae Department of Pathology, Yeungnam
More informationImmunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
Breast Cancer Vol. 14 No. 1 January 2007 Original Article Immunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
More informationPreoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes
Annals of Oncology 19: 675 681, 2008 doi:10.1093/annonc/mdm538 Published online 23 November 2007 Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes B.-W. Park 1,4 *, J.-W.
More informationPrognostic importance of ultrasound BI-RADS classification in breast cancer patients
Japanese Journal of Clinical Oncology, 2015, 45(5) 411 415 doi: 10.1093/jjco/hyv018 Advance Access Publication Date: 10 February 2015 Original Article Original Article Prognostic importance of ultrasound
More informationBREAST CANCER BREAST CANCER
BREAST CANCER George Raptis, M.D., M.B.A Division of Medical Oncology & Hematology College of Physicians & Surgeons Columbia University BREAST CANCER Epidemiology - Commonest cancer in women - About 235,000
More informationDelay of Treatment Initiation Does Not Adversely Affect Survival Outcome in Breast Cancer
pissn 1598-2998, eissn 25-9256 Cancer Res Treat. 216;48(3):962-969 Original Article http://dx.doi.org/1.4143/crt.215.173 Open Access Delay of Treatment Initiation Does Not Adversely Affect Survival Outcome
More informationequally be selected on the basis of RE status of the primary tumour. These initial studies measured RE
Br. J. Cancer (1981) 43, 67 SOLUBLE AND NUCLEAR OESTROGEN RECEPTOR STATUS IN HUMAN BREAST CANCER IN RELATION TO PROGNOSIS R. E. LEAKE*, L. LAING*, C. McARDLEt AND D. C. SMITH$ From the *Department of Biochemistry,
More informationIntro to Cancer Therapeutics
An Intro to Cancer Therapeutics Christopher R. Chitambar, MD Professor of Medicine Division of Hematology & Oncology Froedtert and Medical College of Wisconsin Clinical Cancer Center cchitamb@mcw.edu Intro
More informationARTICLE IN PRESS. doi: /j.ijrobp METAPLASTIC CARCINOMA OF THE BREAST: A RETROSPECTIVE REVIEW
doi:10.1016/j.ijrobp.2005.08.024 Int. J. Radiation Oncology Biol. Phys., Vol. xx, No. x, pp. xxx, 2005 Copyright 2005 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/05/$ see front matter
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More informationNeuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical parameters
& 2004 USCAP, Inc All rights reserved 0893-3952/04 $25.00 www.modernpathology.org Neuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical
More informationIntroduction. Wilfred Truin 1 Rudi M. H. Roumen. Vivianne C. G. Tjan-Heijnen 2 Adri C. Voogd
Breast Cancer Res Treat (2017) 164:133 138 DOI 10.1007/s10549-017-4220-x EPIDEMIOLOGY Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients
More informationDuctal Carcinoma-in-Situ: New Concepts and Controversies
Ductal Carcinoma-in-Situ: New Concepts and Controversies James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
More informationQ&A. Fabulous Prizes. Collecting Cancer Data: Breast 4/4/13. NAACCR Webinar Series Collecting Cancer Data Breast
Collecting Cancer Data Breast NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
More informationOriginal Article Prognostic role of neuroendocrine cell differentiation in human gastric carcinoma
Int J Clin Exp Med 2015;8(5):7837-7842 www.ijcem.com /ISSN:1940-5901/IJCEM0003844 Original Article Prognostic role of neuroendocrine cell differentiation in human gastric carcinoma Tingting Zhang, Dan
More informationClinicopathologic Characteristics and Prognosis of Gastric Cancer in Young Patients
Yonago Acta medica 2012;55:57 61 Clinicopathologic Characteristics and Prognosis of Gastric Cancer in Young Patients Hiroaki Saito, Seigo Takaya, Yoji Fukumoto, Tomohiro Osaki, Shigeru Tatebe and Masahide
More informationPaget's Disease of the Breast: Clinical Analysis of 45 Patients
236 Paget's Disease of the Breast: Clinical Analysis of 45 Patients Mingfian Yang Hao Long Jiehua He Xi Wang Zeming Xie Department of Thoracic Oncology, Cancer Center of Sun Yat-sen University, Guangzhou
More informationCorrelation Between GATA-3, Ki67 and p53 Expressions to Histopathology Grading of Breast Cancer in Makassar, Indonesia
Cancer Research Journal 2016; 4(3): 43-47 http://www.sciencepublishinggroup.com/j/crj doi: 10.11648/j.crj.20160403.11 ISSN: 2330-8192 (Print); ISSN: 2330-8214 (Online) Correlation Between GATA-3, Ki67
More informationLessons Learnt from Neoadjuvant Hormone Therapy. 10 Lessons Learnt from Neoadjuvant Endocrine Therapy. Lesson 1
Lessons Learnt from Neoadjuvant Hormone Therapy Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh 10 Lessons Learnt from Neoadjuvant Endocrine Therapy 10 Lessons Learnt from Neoadjuvant
More informationLessons Learnt from Neoadjuvant Hormone Therapy. Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh
Lessons Learnt from Neoadjuvant Hormone Therapy Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh 10 Lessons Learnt from Neoadjuvant Endocrine Therapy 10 Lessons Learnt from Neoadjuvant
More informationProblems in staging breast carcinoma
Problems in staging breast carcinoma Primary systemic therapy (PST) of breast carcinoma pathologists tasks Dr. Janina Kulka, 2nd Department of Pathology, Semmelweis University Budapest Austro-Hungarian
More informationOriginal Article Long term prognosis of ductal carcinoma in situ with microinvasion: a retrospective cohort study
Int J Clin Exp Pathol 2018;11(5):2665-2674 www.ijcep.com /ISSN:1936-2625/IJCEP0072542 Original Article Long term prognosis of ductal carcinoma in situ with microinvasion: a retrospective cohort study Tianjie
More informationDepartment of Endocrine & Breast Surgery Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
Department of Endocrine & Breast Surgery Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India Evidence-Based Pragmatic SGPGI Breast Cancer Management Protocols (Summary) Background:
More informationFAQs for UK Pathology Departments
FAQs for UK Pathology Departments This is an educational piece written for Healthcare Professionals FAQs for UK Pathology Departments If you would like to discuss any of the listed FAQs further, or have
More informationLong term survival study of de-novo metastatic breast cancers with or without primary tumor resection
Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection Dr. Michael Co Division of Breast Surgery Queen Mary Hospital The University of Hong Kong Conflicts
More informationInes Buccimazza 16 TH UP CONTROVERSIES AND PROBLEMS IN SURGERY SYMPOSIUM
BILATERAL MASTECTOMY IS NOT ROUTINELY JUSTIFIED IN PATIENTS WITH BILATERAL AXILLARY LYMPHADENOPATHY AND ONLY ONE DETECTABLE PRIMARY BREAST CANCER LESION SURGERY SYMPOSIUM Ines Buccimazza Breast Unit Department
More informationBackground: Case Report: Conclusions: Neoplasm Metastasis Breast Neoplasms therapy Aromatase Inhibitors. MeSH Keywords:
ISSN 1941-5923 DOI: 10.12659/AJCR.890023 Received: 2013.11.11 Accepted: 2013.12.08 Published: 2014.02.24 Long-term complete remission of metastatic breast cancer, induced by a steroidal aromatase inhibitor
More informationPatient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS
More informationProceedings of the 36th World Small Animal Veterinary Congress WSAVA
www.ivis.org Proceedings of the 36th World Small Animal Veterinary Congress WSAVA Oct. 14-17, 2011 Jeju, Korea Next Congress: Reprinted in IVIS with the permission of WSAVA http://www.ivis.org 14(Fri)
More informationPrognostic Factors for Node-Negative Advanced Gastric Cancer after Curative Gastrectomy
pissn : 293-582X, eissn : 293-564 J Gastric Cancer 26;6(3):6-66 http://dx.doi.org/.523/jgc.26.6.3.6 Original Article Prognostic Factors for Node-Negative Advanced Gastric Cancer after Curative Gastrectomy
More informationEffects of postmastectomy radiotherapy on prognosis in different tumor stages of breast cancer patients with positive axillary lymph nodes
Cancer Biol Med 2014;11:123-129. doi: 10.7497/j.issn.2095-3941.2014.02.007 ORIGINAL ARTICLE Effects of postmastectomy radiotherapy on prognosis in different tumor stages of breast cancer patients with
More information